person · Reporting owner
Teyssedou Lenaic Nathanael
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Addex Therapeutics Ltd.ADXN · Entity 8301 | PRINCIPAL ACCOUNTING OFFICER | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Addex Therapeutics Ltd.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.16 · Expires 2027-12-31 | Direct | 565,138 |
Reported balance
After 2026-09-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-02 · Disposition to issuer · Disposed 37,770 · Balance 565,138 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2027-12-31 | Direct | 602,908 |
Reported balance
After 2026-09-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-02 · Grant · Acquired 37,770 · Balance 602,908 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.16 · Expires 2028-05-31 | Direct | 543,378 |
Reported balance
After 2026-09-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-02 · Disposition to issuer · Disposed 59,530 · Balance 543,378 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2028-05-31 | Direct | 602,908 |
Reported balance
After 2026-09-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-02 · Grant · Acquired 59,530 · Balance 602,908 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.16 · Expires 2030-03-31 | Direct | 592,908 |
Reported balance
After 2026-09-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-02 · Disposition to issuer · Disposed 10,000 · Balance 592,908 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2030-03-31 | Direct | 602,908 |
Reported balance
After 2026-09-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-02 · Grant · Acquired 10,000 · Balance 602,908 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.16 · Expires 2031-05-16 | Direct | 572,908 |
Reported balance
After 2026-09-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-02 · Disposition to issuer · Disposed 30,000 · Balance 572,908 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2031-05-16 | Direct | 602,908 |
Reported balance
After 2026-09-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-02 · Grant · Acquired 30,000 · Balance 602,908 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.16 · Expires 2032-04-11 | Direct | 537,288 |
Reported balance
After 2026-09-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-02 · Disposition to issuer · Disposed 65,620 · Balance 537,288 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2032-04-11 | Direct | 602,908 |
Reported balance
After 2026-09-02 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-02 · Grant · Acquired 65,620 · Balance 602,908 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.16 · Expires 2032-10-04 | Direct | 512,379 |
Reported balance
After 2026-09-02 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-02 · Disposition to issuer · Disposed 90,529 · Balance 512,379 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2032-10-04 | Direct | 602,908 |
Reported balance
After 2026-09-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-02 · Grant · Acquired 90,529 · Balance 602,908 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.05 · Expires 2033-05-11 | Direct | 393,934 |
Reported balance
After 2026-09-02 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-02 · Disposition to issuer · Disposed 208,974 · Balance 393,934 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2033-05-11 | Direct | 602,908 |
Reported balance
After 2026-09-02 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-09-02 · Grant · Acquired 208,974 · Balance 602,908 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2034-01-07 | Direct | 502,423 |
Reported balance
After 2026-09-02 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-09-02 · Disposition to issuer · Disposed 100,485 · Balance 502,423 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2034-01-07 | Direct | 602,908 |
Reported balance
After 2026-09-02 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-09-02 · Grant · Acquired 100,485 · Balance 602,908 F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.
F2: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | GrantStock-option (Right to Buy) · Derivative | 100,485 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 16 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,908 Underlying: Common Stock · 100,485 shares Expires 2034-01-07 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | Disposition to issuerStock-option (Right to Buy) · Derivative | 100,485 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 15 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,423 Underlying: Common Stock · 100,485 shares Expires 2034-01-07 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | GrantStock-option (Right to Buy) · Derivative | 208,974 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 14 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,908 Underlying: Common Stock · 208,974 shares Expires 2033-05-11 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | Disposition to issuerStock-option (Right to Buy) · Derivative | 208,974 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 13 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,934 Underlying: Common Stock · 208,974 shares Expires 2033-05-11 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | GrantStock-option (Right to Buy) · Derivative | 90,529 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 12 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,908 Underlying: Common Stock · 90,529 shares Expires 2032-10-04 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | Disposition to issuerStock-option (Right to Buy) · Derivative | 90,529 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 11 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,379 Underlying: Common Stock · 90,529 shares Expires 2032-10-04 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | GrantStock-option (Right to Buy) · Derivative | 65,620 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 10 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,908 Underlying: Common Stock · 65,620 shares Expires 2032-04-11 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | Disposition to issuerStock-option (Right to Buy) · Derivative | 65,620 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 9 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 537,288 Underlying: Common Stock · 65,620 shares Expires 2032-04-11 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | GrantStock-option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 8 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,908 Underlying: Common Stock · 30,000 shares Expires 2031-05-16 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | Disposition to issuerStock-option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 7 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 572,908 Underlying: Common Stock · 30,000 shares Expires 2031-05-16 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | GrantStock-option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 6 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,908 Underlying: Common Stock · 10,000 shares Expires 2030-03-31 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | Disposition to issuerStock-option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 5 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 592,908 Underlying: Common Stock · 10,000 shares Expires 2030-03-31 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | GrantStock-option (Right to Buy) · Derivative | 59,530 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 4 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,908 Underlying: Common Stock · 59,530 shares Expires 2028-05-31 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | Disposition to issuerStock-option (Right to Buy) · Derivative | 59,530 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 3 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,378 Underlying: Common Stock · 59,530 shares Expires 2028-05-31 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | GrantStock-option (Right to Buy) · Derivative | 37,770 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 2 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,908 Underlying: Common Stock · 37,770 shares Expires 2027-12-31 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:11 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | Disposition to issuerStock-option (Right to Buy) · Derivative | 37,770 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001104659-26-105509 · tm2624769-5_4seq1.xml · derivative · entry 1 Teyssedou Lenaic Nathanael · CIK 0002123881 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,138 Underlying: Common Stock · 37,770 shares Expires 2027-12-31 F2 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.